// App-Quantinova.ai

POS0687 (2021) : A RANDOMISED DOSE RANGING, PLACEBO-CONTROLLED, PHASE II STUDY ASSESSING THE EFFICACY AND SAFETY OF BI 655064, AN ANTAGONISTIC ANTI-CD40 ANTIBODY, IN PATIENTS WITH LUPUS NEPHRITIS

Researchers

Presenter

  • D. Jayne

Principal Investigators

  • J. Steffgen

  • J. Romero-Diaz

  • H. Amano

  • K. Noppakun

  • S. Padula

  • J. Wu

  • S. Visvanathan

  • R. Furie

Medical Centers

  • University of Cambridge, Department of Oncology, Cambridge, United Kingdom

  • Boehringer Ingelheim International GmbH, Inflammation Medicine, Ingelheim am Rhein, Germany

  • Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran, Immunology and Rheumatology, Mexico City, Mexico

  • Juntendo University Hospital, Department of Medicine, Japan, Japan

  • Chiang Mai University, Department of Pediatrics, Chiang Mai, Thailand

  • Angeles University Foundation Medical Center, Rheumatology, Angeles City, Philippines

  • Mary Mediatrix Medical Center, Internal Medicine, Lipa City, Philippines

  • SCS Boehringer Ingelheim, Clinical Operations, Brussels, Belgium

  • Boehringer Ingelheim Pharmaceuticals, Inc., Biostatistics and Data Sciences, Ridgefield, United States

  • Boehringer Ingelheim International GmbH, Inflammation Medicine, Ingelheim am Rhein, Germany

  • Boehringer Ingelheim International GmbH, Pharmacovigilance Corporate, Ingelheim, Germany

  • Boehringer Ingelheim Pharmaceuticals, Inc, Translational Medicine and Clinical Pharmacology, Ridgefield, United States

  • Northwell Health and Zucker School of Medicine at Hofstra/Northwell, Department of Rheumatology, Great Neck, United States of America

Locations

  • United Kingdom

  • Germany

  • Mexico

  • Japan

  • Thailand

  • Philippines

  • Belgium

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Endocrine/metabolic Diseases (ME)

  • Nephrology

Disease

  • Lupus nephritis

  • Albuminuria

  • Nephritis

  • Lupus

Biomarkers

  • Creatinine

Drug/Treatment

  • BI 655064

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • II

Study Id's

  • NCT02770170

Sponsors

  • Boehringer Ingelheim

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved